Cargando…
Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis
PURPOSE: The objective of this study was to investigate the antitumor activity, targeting capability, and mechanism of the developed nanodrug consisting of doxorubicin and exosome (Exo-Dox) derived from mesenchymal stem cells in vitro and in vivo. METHODS: The exosomes were isolated with Exosome Iso...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359454/ https://www.ncbi.nlm.nih.gov/pubmed/35959282 http://dx.doi.org/10.2147/IJN.S372851 |
_version_ | 1784764141855047680 |
---|---|
author | Wei, Hongxiang Chen, Fei Chen, Jinyuan Lin, Huangfeng Wang, Shenglin Wang, Yunqing Wu, Chaoyang Lin, Jianhua Zhong, Guangxian |
author_facet | Wei, Hongxiang Chen, Fei Chen, Jinyuan Lin, Huangfeng Wang, Shenglin Wang, Yunqing Wu, Chaoyang Lin, Jianhua Zhong, Guangxian |
author_sort | Wei, Hongxiang |
collection | PubMed |
description | PURPOSE: The objective of this study was to investigate the antitumor activity, targeting capability, and mechanism of the developed nanodrug consisting of doxorubicin and exosome (Exo-Dox) derived from mesenchymal stem cells in vitro and in vivo. METHODS: The exosomes were isolated with Exosome Isolation Kit, and the Exo-Dox was prepared by mixing exosome with Dox-HCl, desalinizing with triethylamine and then dialyzing against PBS overnight. The exosome and Exo-Dox were examined by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). The antitumor activity, targeting capability, and mechanism of the developed Exo-Dox were evaluated by cell viability assay, histological and immunofluorescence analysis and in vivo imaging system. RESULTS: NTA results showed the size of the exosomes had increased from 141.6 nm to 178.1 nm after loading with doxorubicin. Compared with free Dox, the Exo-Dox exhibited higher cytotoxicity against osteosarcoma MG63 cells, HOS cells, and 143B cells than free Dox, the half-maximal inhibitory concentrations (IC50) of Dox, Exo-Dox were calculated to be 0.178 and 0.078 μg mL(−1) in MG63 cells, 0.294 and 0.109μg mL(−1) in HOS cells, 0.315 and 0.123 μg mL(−1) in 143B cells, respectively. The in vivo imaging showed that MSC derived Exo could serve as a highly efficient delivery vehicle for targeted drug delivery. The immunohistochemistry and histology analysis indicated that compared with the free Dox group, the Ki67-positive cells and cardiotoxicity in Exo-Dox group were significantly decreased. CONCLUSION: Our results suggested that MSC-derived Exo could be excellent nanocarriers used to deliver chemotherapeutic drug Dox specifically and efficiently in osteosarcoma, resulting in enhanced toxicity against osteosarcoma and less toxicity in heart tissue. We further demonstrated the targeting capability of Exo was due to the chemotaxis of MSC-derived exosomes to osteosarcoma cells via SDF1-CXCR4 axis. |
format | Online Article Text |
id | pubmed-9359454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-93594542022-08-10 Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis Wei, Hongxiang Chen, Fei Chen, Jinyuan Lin, Huangfeng Wang, Shenglin Wang, Yunqing Wu, Chaoyang Lin, Jianhua Zhong, Guangxian Int J Nanomedicine Original Research PURPOSE: The objective of this study was to investigate the antitumor activity, targeting capability, and mechanism of the developed nanodrug consisting of doxorubicin and exosome (Exo-Dox) derived from mesenchymal stem cells in vitro and in vivo. METHODS: The exosomes were isolated with Exosome Isolation Kit, and the Exo-Dox was prepared by mixing exosome with Dox-HCl, desalinizing with triethylamine and then dialyzing against PBS overnight. The exosome and Exo-Dox were examined by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). The antitumor activity, targeting capability, and mechanism of the developed Exo-Dox were evaluated by cell viability assay, histological and immunofluorescence analysis and in vivo imaging system. RESULTS: NTA results showed the size of the exosomes had increased from 141.6 nm to 178.1 nm after loading with doxorubicin. Compared with free Dox, the Exo-Dox exhibited higher cytotoxicity against osteosarcoma MG63 cells, HOS cells, and 143B cells than free Dox, the half-maximal inhibitory concentrations (IC50) of Dox, Exo-Dox were calculated to be 0.178 and 0.078 μg mL(−1) in MG63 cells, 0.294 and 0.109μg mL(−1) in HOS cells, 0.315 and 0.123 μg mL(−1) in 143B cells, respectively. The in vivo imaging showed that MSC derived Exo could serve as a highly efficient delivery vehicle for targeted drug delivery. The immunohistochemistry and histology analysis indicated that compared with the free Dox group, the Ki67-positive cells and cardiotoxicity in Exo-Dox group were significantly decreased. CONCLUSION: Our results suggested that MSC-derived Exo could be excellent nanocarriers used to deliver chemotherapeutic drug Dox specifically and efficiently in osteosarcoma, resulting in enhanced toxicity against osteosarcoma and less toxicity in heart tissue. We further demonstrated the targeting capability of Exo was due to the chemotaxis of MSC-derived exosomes to osteosarcoma cells via SDF1-CXCR4 axis. Dove 2022-08-04 /pmc/articles/PMC9359454/ /pubmed/35959282 http://dx.doi.org/10.2147/IJN.S372851 Text en © 2022 Wei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wei, Hongxiang Chen, Fei Chen, Jinyuan Lin, Huangfeng Wang, Shenglin Wang, Yunqing Wu, Chaoyang Lin, Jianhua Zhong, Guangxian Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis |
title | Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis |
title_full | Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis |
title_fullStr | Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis |
title_full_unstemmed | Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis |
title_short | Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis |
title_sort | mesenchymal stem cell derived exosomes as nanodrug carrier of doxorubicin for targeted osteosarcoma therapy via sdf1-cxcr4 axis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359454/ https://www.ncbi.nlm.nih.gov/pubmed/35959282 http://dx.doi.org/10.2147/IJN.S372851 |
work_keys_str_mv | AT weihongxiang mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT chenfei mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT chenjinyuan mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT linhuangfeng mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT wangshenglin mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT wangyunqing mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT wuchaoyang mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT linjianhua mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis AT zhongguangxian mesenchymalstemcellderivedexosomesasnanodrugcarrierofdoxorubicinfortargetedosteosarcomatherapyviasdf1cxcr4axis |